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Re-evaluation of the
phenotype caused by the
common MATR3 p.Ser85Cys
mutation in a new family
INTRODUCTION
Late-onset autosomal dominant vocal cord
and pharyngeal distal myopathy (VCPDM)
was ﬁrst described in an American family.1
A p.Ser85Cys mutation in MATR3 gene
was later identiﬁed in this family, and also
in one Bulgarian family and very recently,
in seven families—six German and one
Asian.2–4 Muscle pathology of VCPDM
was dominated by rimmed-vacuolar ﬁbre
degeneration.1 2 This year, two other
mutations in MATR3, p.Phe115Cys and
p.Thr622Ala, have been reported to cause
autosomal dominant amyotrophic lateral
sclerosis (ALS).5 The original American
p.Ser85Cys mutated family was
re-evaluated and the authors stated:
“These clinical ﬁndings supported reclassi-
ﬁcation of this condition as slowly progres-
sive ALS, and the presence of upper motor
neuron signs in the form of brisk reﬂexes
ruled out myopathy as the only cause of
disease in this family.”5
We report a new family with the p.
Ser85Cys mutation in MATR3, in which
muscle atrophy and weakness are caused
by progressive degenerative myopathy
without any evidence of lower motor
neuron defects.
METHODS
We investigated an American family with
four affected siblings. Patients II.1, II.2 and
II.4 were more extensively examined and
followed for 7, 9 and 8 years, respectively.
The father and one of his brothers were
affected (ﬁgure 1A). Muscle MRI was per-
formed in the proband (II.2) and in the
younger brother (II.4). Muscle biopsies
were obtained from three patients and
examined by standard histochemical and
immunohistochemical stainings with anti-
bodies for Matrin 3, TDP-43, p62, SMI-31
and myosin A4.74, slow (MHCs), neonatal
(MHCn) and developmental (MHCd) iso-
forms. Immunoﬂuorescence analysis was
performed with conventional methods
using antibodies for G3BP and TIA1
C-terminus. Matrin 3 distribution was
analysed from soluble cytoplasmic and
nuclear fractions using western blotting.
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Blood samples of all siblings in gener-
ation II were obtained and DNA was
extracted by standard methods. Whole
exome sequencing was performed on
patient II.2 at ATLAS Biolabs GmbH
using SeqCap EZ Human Exome Library
V.2.0 (Roche NimbleGen), and captured
DNA was sequenced on Illumina HiSeq
2000 platform, 2×100 bp. Reads were
processed following the Genome Analysis
Toolkit best practices pipeline and the
Human Gene Mutation Database was
used to detect previously reported patho-
genic mutations. Sanger sequencing was
performed to conﬁrm the ﬁndings.
RESULTS
The age of onset ranged from 31 to
48 years, and the ﬁrst manifestation was
either weakness in the hands or legs causing
difﬁculty in dexterity, or standing on heels
and toes. The weakness slowly progressed
to proximal upper and lower limb muscles.
Wasting of the small hand muscles was
evident followed by atrophy in the distal
lower leg and forearm (ﬁgure 1B).
Waddling and steppage gait was observed.
Fasciculations were absent in all siblings. In
two patients, brisk reﬂexes without clonus
or spread were noted; there were no deﬁnite
pathological pyramidal tract reﬂexes
(Hoffman, crossed adductors, Babinski
sign). Several years after disease onset, two
patients had mild to moderate hypophonia
and dysphagia. Two patients did not have
respiratory symptoms; the other two had
dyspnoea on exertion, reduced forced vital
capacity (50%), or both.
Creatine kinase (CK) levels were normal
or marginally elevated. Electromyography
studies of all patients were consistent with
myopathic changes. Fasciculations were
absent. No chronic neurogenic changes
(eg, large amplitude or long duration
motor unit potentials) were observed in
any of the studies. MRI showed marked
fatty degeneration of dystrophic type in
soleus and medial gastrocnemius in both
patients studied (ﬁgure 1C). Less severe
changes were observed in the anterolateral
lower leg compartment and hamstrings in
II.4. In muscle biopsy taken from the left
tibialis anterior (II.2), there were numer-
ous rimmed-vacuolated ﬁbres (ﬁgure 1D).
MyHC double staining showed a normal
ﬁbre type distribution without grouping.
MHCd labelled most of the highly atro-
phic ﬁbres and these were reactive for
MHCn, although with less intensity in the
moderately atrophic ﬁbres and not in
MHCd negative ﬁbres. Matrin 3 immuno-
histochemistry showed a loss of protein in
the central parts of myonuclei (ﬁgure 1D).
Myoﬁbrillar myopathy markers myotilin,
desmin, αB-crystallin, and ectopic cyto-
plasmic dystrophin were negative, whereas
TDP-43, p62, and SMI-31 accumulated in
rimmed-vacuolar ﬁbres (data not shown).
Electron microscopy showed highly convo-
luted myonuclei. In immunoﬂuorescent
analysis, the TDP-43 binding partner TIA1
and TIA1 ligand G3BP showed increased
expression. Matrin 3 analysed by western
blotting showed no abnormalities com-
pared to control (not shown).
Figure 1 Pedigree and muscle ﬁndings of the family. Pedigree of the family (A). Wasting of the ﬁrst dorsal interossei and thenar muscle of patient
II.2 is seen on the right side (B). T1-weighted axial MRI scans of the lower legs of patient II.2 show prominent fatty degenerative changes in the
soleus and medial gastrocnemius selectively sparing the lateral gastrocnemius and without signiﬁcant changes in the anterior compartment (C). H&E
stain section shows ﬁbres with rimmed-vacuolar changes. Myosin heavy chain (MyHC) double staining with normal ﬁbre type distribution, variation
in ﬁbre size ranging from highly atrophic rounded ﬁbres to hypertrophic ﬁbres, and numerous mostly rounded atrophic ﬁbres of both type 1 (brown)
and type IIa (red). Myosin heavy chain neonatal (MHCn) and developmental (MHCd) antibody reactivity in highly atrophic ﬁbres and in moderately
atrophic ﬁbres. In internalised nuclei the central part showed depletion of Matrin 3 immunostaining with strong irregular label in the nuclear
membrane. Matrin 3 normal control muscle showed a uniform reactivity in all myonuclei. Electron micrograph (EM) of the abnormally convoluted
nuclear membrane.
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Exome sequencing revealed a known
mutation in MATR3: c.254C>G, p.
Ser85Cys (NM_199189.2).2 The muta-
tion was Sanger sequenced and was
present in all four of the affected siblings.
DISCUSSION
We report a new VCPDM family with the
p.Ser85Cys mutation in MATR3 showing
less bulbar involvement, but respiratory
failure in some cases. MATR3 as a cause
of ALS was initially reported by Johnson
et al5 based on the identiﬁcation of segre-
gating mutations in several families and
subsequently replicated in exome data
derived from an independent cohort of
patients diagnosed with familial ALS.6
The pattern of combined features of
ALS and myopathy has been recognised
with other ALS-causing genes such as
CHCHD10, VCP, hnRNPA1 and
hnRNPA2B1.7–11 An assessment for a
potential motor neuron component in our
family showed brisk reﬂexes raising the
possibility of minor upper motor neuron
pathology, but there were no lower motor
neuron abnormalities to account for the
muscle atrophy.
Late-onset distal weakness with vocal
cord and pharyngeal involvement has been
the clinical hallmark of VCPDM.1 2
However, bulbar symptoms can be absent
in the beginning, as observed in our
patients, and in a report of 16 German
patients.3 Respiratory insufﬁciency was
evident in half of our siblings. The pheno-
type with this mutation is variable and the
known hallmarks of the disease, dysphagia
and dysphonia, can be subtle or absent.
The distinct wasting of the ﬁrst dorsal
interossei and thenar muscles, with relative
sparing of the hypothenar, was present in
our patients, but never associated with
clinical or electrophysiological fascicula-
tions in muscles of the hands or elsewhere.
Furthermore, motor unit potentials
(MUPs) did not show increased duration
or amplitude indicative of a chronic neuro-
genic process, but were clearly decreased
in size indicating a myopathic process.
Similarly, no changes compatible with a
neurogenic process were observed on
muscle biopsy. More than 10% of ﬁbres
expressed MHCd, in contrast to neuro-
genic atrophy where MHCn reactive atro-
phic ﬁbres are far more frequent than
MHCd reactive ﬁbres. We, thus, conclude
that with the MATR3 p.Ser85Cys mutation
in our family, the major process causing
muscle atrophy and functional limitations
is myopathic loss of muscle tissue.
Matrin 3 is a component of the nuclear
matrix and has been associated with
splicing and DNA replication.12
The abnormal nuclear distribution of
Matrin 3 in immunohistochemistry with
normal result in western blotting suggests
that the disease pathomechanisms do not
involve quantitative changes in Matrin 3
expression, but rather mislocalisation of the
protein. Matrin 3 interacts with TDP-43, a
protein linked to ALS/frontotemporal
dementia. TDP-43 and other autophagic
markers, p62 and SMI-31, were compo-
nents of the rimmed-vacuolar pathology in
our patients. Increase of TIA1 reactive cyto-
plasmic granules and increased G3BP label-
ling suggest they are involved. G3BP is a
key component of stress granules and a
ligand of Matrin 3, which may contribute
to the phenotype similarity with Welander
distal myopathy.
The cases reported here show that dis-
tinguishing between myogenic and neuro-
genic pathomechanisms requires careful
assessment of clinical, electrophysio-
logical, muscle morphological and muscle
MRI techniques.
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